Fasting Ketone Bodies and Incident Type 2 Diabetes in the General Population. 2023

Tamas Szili-Torok, and Martin H de Borst, and Erwin Garcia, and Ron T Gansevoort, and Robin P F Dullaart, and Margery A Connelly, and Stephan J L Bakker, and Uwe J F Tietge
Department of Internal Medicine, University Medical Center Groningen, Groningen, the Netherlands.

With rising incidence and prevalence of type 2 diabetes, prevention including identification of prospective biomarkers becomes increasingly relevant. Although ketone bodies recently received a renewed interest as potential biomarkers, data linking these metabolites to diabetes risk are scarce. Therefore, the present prospective study investigated a potential association between fasting ketone bodies and incident type 2 diabetes in the general population. This study from the PREVEND cohort included 3,307 participants from the general population initially free of diabetes or impaired fasting glucose. Baseline fasting ketone body concentrations were measured by nuclear magnetic resonance spectroscopy. One hundred twenty-six participants (3.8%) developed type 2 diabetes during a median (interquartile range) follow-up of 7.3 (6.3-7.6) years. In Kaplan-Meier analysis, sex-stratified ketone body levels strongly positively associated with incident type 2 diabetes, which was confirmed in Cox regression analyses adjusted for several potential confounders. There was no significant interaction by sex. Both 3-β-hydroxybutyrate and acetoacetate+acetone individually associated with incident type 2 diabetes. In conclusion, fasting plasma ketone body levels are strongly positively associated with incident type 2 diabetes in the general population independent of several other recognized risk factors. These results may have important implications for diabetes prevention including dietary strategies. The identification of biomarkers that predict type 2 diabetes is increasingly relevant for personalized medicine strategies. Data regarding ketone bodies and incident type 2 diabetes are scarce. This study shows that ketone bodies, either combined or as individual subspecies, are strongly associated with incident type 2 diabetes in the general population, independent of potential confounders. These results may have important implications for diabetes prevention including dietary strategies.

UI MeSH Term Description Entries
D007657 Ketone Bodies The metabolic substances ACETONE; 3-HYDROXYBUTYRIC ACID; and acetoacetic acid (ACETOACETATES). They are produced in the liver and kidney during FATTY ACIDS oxidation and used as a source of energy by the heart, muscle and brain. Acetone Bodies,Bodies, Acetone,Bodies, Ketone
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005215 Fasting Abstaining from FOOD. Hunger Strike,Hunger Strikes,Strike, Hunger,Strikes, Hunger
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D020155 3-Hydroxybutyric Acid BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver. 3-Hydroxybutyrate,beta-Hydroxybutyrate,(+ -)-3-Hydroxybutyric Acid,beta-Hydroxybutyric Acid,3 Hydroxybutyrate,3 Hydroxybutyric Acid,beta Hydroxybutyrate,beta Hydroxybutyric Acid

Related Publications

Tamas Szili-Torok, and Martin H de Borst, and Erwin Garcia, and Ron T Gansevoort, and Robin P F Dullaart, and Margery A Connelly, and Stephan J L Bakker, and Uwe J F Tietge
June 2022, Cardiovascular diabetology,
Tamas Szili-Torok, and Martin H de Borst, and Erwin Garcia, and Ron T Gansevoort, and Robin P F Dullaart, and Margery A Connelly, and Stephan J L Bakker, and Uwe J F Tietge
September 2023, The Journal of clinical endocrinology and metabolism,
Tamas Szili-Torok, and Martin H de Borst, and Erwin Garcia, and Ron T Gansevoort, and Robin P F Dullaart, and Margery A Connelly, and Stephan J L Bakker, and Uwe J F Tietge
February 2019, Diabetologia,
Tamas Szili-Torok, and Martin H de Borst, and Erwin Garcia, and Ron T Gansevoort, and Robin P F Dullaart, and Margery A Connelly, and Stephan J L Bakker, and Uwe J F Tietge
April 2021, Clinical endocrinology,
Tamas Szili-Torok, and Martin H de Borst, and Erwin Garcia, and Ron T Gansevoort, and Robin P F Dullaart, and Margery A Connelly, and Stephan J L Bakker, and Uwe J F Tietge
April 2001, JAMA,
Tamas Szili-Torok, and Martin H de Borst, and Erwin Garcia, and Ron T Gansevoort, and Robin P F Dullaart, and Margery A Connelly, and Stephan J L Bakker, and Uwe J F Tietge
December 2019, Diagnostics (Basel, Switzerland),
Tamas Szili-Torok, and Martin H de Borst, and Erwin Garcia, and Ron T Gansevoort, and Robin P F Dullaart, and Margery A Connelly, and Stephan J L Bakker, and Uwe J F Tietge
March 1999, Diabetes,
Tamas Szili-Torok, and Martin H de Borst, and Erwin Garcia, and Ron T Gansevoort, and Robin P F Dullaart, and Margery A Connelly, and Stephan J L Bakker, and Uwe J F Tietge
September 1970, The Journal of clinical investigation,
Tamas Szili-Torok, and Martin H de Borst, and Erwin Garcia, and Ron T Gansevoort, and Robin P F Dullaart, and Margery A Connelly, and Stephan J L Bakker, and Uwe J F Tietge
September 2020, Diabetes care,
Tamas Szili-Torok, and Martin H de Borst, and Erwin Garcia, and Ron T Gansevoort, and Robin P F Dullaart, and Margery A Connelly, and Stephan J L Bakker, and Uwe J F Tietge
August 2018, Hepatology research : the official journal of the Japan Society of Hepatology,
Copied contents to your clipboard!